Uso de los inhibidores del cotransportador sodio-glucosa tipo 2 para reducir complicaciones cardiológicas y renales en pacientes con diabetes tipo 2

Abstract

One of the most common diseases in the world is diabetes, specifically type 2, which is mainly caused by insulin resistance and hyperglycemia. Recently, the ineffectiveness of metformin monotherapy in certain patients results in the appearance of complications, mainly those of a cardiological and renal type, therefore, it has been seen necessary to implement new classes of antidiabetics to achieve correct management in this type of patients. Recent research has found that the use of sodium-glucose cotransporter 2 inhibitors in people with type 2 diabetes and at risk of heart or kidney complications is favorable, as these drugs have been shown to reduce the chance of heart events , mainly heart failure, in addition to preventing the progression or development of chronic or end-stage renal disease, all this due to its hypoglycemic, anti-inflammatory and metabolic properties, which prevent hyperfiltration at the glomerular level and reduce blood pressure levels, achieving positive effects on heart and kidney function in patients suffering from type 2 diabetes.